FDA relying on listings to find marketing abuses

In recent warning letters to Glenmark Pharmaceuticals and Konec for marketing unapproved and misbranded nitroglycerin tablets, the FDA relies solely on drug listing information. The reliance is "notable," according to legal experts at Hyman, Phelps & McNamara.

Although drug listings have been cited before in warning letters, such mentions usually accompany manufacturing practice observations made by inspectors during a facility visit, explain Kurt Karst and Dara Katcher Levy. "Expect to see more Warning Letters directly from the Office of Compliance based solely on drug listing information," they write.

The tactic is all the more important given the FDA's Unapproved Drugs Initiative launched in 2006.  In the final guidance Marketed Unapproved Drugs-Compliance Policy Guide, the regulator outlines how it intends to exercise its enforcement discretion while emphasizing that illegally marketed drugs require agency approval.

- see the article
- here's the guidance

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.